Difference between revisions of "Cortes JE, et al. Am. J. Hematol. (2018) cited as Ref 614 in DOI: 10.1038/s41392-020-0110-5 (Q9877)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Publication Date (P100): 2018, #quickstatements; #temporary_batch_1590002823654)
(‎Created claim: Page(s) (P105): 1301-1310, #quickstatements; #temporary_batch_1590074839150)
 
(3 intermediate revisions by the same user not shown)
Property / Published In Name String
 +
Am. J. Hematol.
Property / Published In Name String: Am. J. Hematol. / rank
 +
Normal rank
Property / Volume
 +
93
Property / Volume: 93 / rank
 +
Normal rank
Property / title
 +
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results (English)
Property / title: Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results (English) / rank
 +
Normal rank
Property / Page(s)
 +
1301-1310
Property / Page(s): 1301-1310 / rank
 +
Normal rank

Latest revision as of 15:47, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Cortes JE, et al. Am. J. Hematol. (2018) cited as Ref 614 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Cortes JE
    0 references
    0 references
    2018
    0 references
    Am. J. Hematol.
    0 references
    93
    0 references
    Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results (English)
    0 references
    1301-1310
    0 references